Biotech's most exciting startups of 2026: Meet this year's Endpoints 11
The 2026 Endpoints 11 list features promising biotech startups, including Azalea Therapeutics and Medici, which focus on cancer immunotherapy and CAR-T technologies. These startups, founded by Parker Institute investigators, showcase the transition of academic research into commercial ventures within oncology. The list recognizes companies making significant strides in biotech innovation.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Azalea Therapeutics focuses on cancer immunotherapy and CAR-T technologies.
- ✓ Medici was founded by Parker Institute investigators.
What changed
The latest update on the Endpoints 11 list reveals recent funding rounds and advancements in the biotech sector, providing insights into the current state of biotech innovation.
Live updates
-
Endpoints 11 list highlights 2026's high-potential biotech startups
The 2026 Endpoints 11 list features promising biotech startups, including Azalea Therapeutics and Medici, which focus on cancer immunotherapy and CAR-T technologies. These startups, founded by Parker Institute investigators, showcase the transition of academic research into commercial ventures within oncology. The list recognizes companies making significant strides in biotech innovation.
Why it matters
The Endpoints 11 list is a recognition of high-potential biotech startups. This year's list includes companies like Azalea Therapeutics and Medici, which are advancing cancer treatment technologies. The recognition of these startups highlights the growing trend of academic research being translated into commercial ventures, particularly in oncology. This transition is crucial for the development of new treatments and therapies.
What is confirmed
- Azalea Therapeutics focuses on cancer immunotherapy and CAR-T technologies.
- Medici was founded by Parker Institute investigators.
Still unconfirmed
- The BioStartups community is driving innovation in biotechnology and healthcare.
What to watch next
- Further funding rounds for Endpoints 11 listed companies
- Advancements in cancer immunotherapy and CAR-T technologies
- The impact of academic research on commercial biotech ventures
confidence 90%Sources used for this update (3)
- www.statnews.com — ESMO 2026: The STAT Recap
- indexed.vc — Recently Funded Biotech Companies 2026 - indexed.vc
- thebiostartups.com — The BioStartups - Accelerating Life Sciences Innovation
-
Endpoints 11 list spotlights biotech startups
The 2026 Endpoints 11 list recognizes high-potential biotech startups. Azalea Therapeutics and Medici, founded by Parker Institute investigators, are on the list. Azalea focuses on cancer immunotherapy and CAR-T technologies. These startups' recognitions highlight the transition of academic research into commercial ventures within oncology.
Why it matters
The biotech sector is closely watching these startups as they advance innovative treatments. Their technical approaches and leadership are key factors in their recognitions. The Endpoints 11 list identifies startups with potential for significant impact. This list is relevant for understanding emerging trends in biotech.
What is confirmed
- Azalea Therapeutics and Medici earned spots on the 2026 Endpoints 11 list.
- Azalea Therapeutics focuses on cancer immunotherapy and CAR-T technologies.
- The Endpoints 11 list recognizes high-potential biotech startups based on technical approach and leadership.
- Value Add VC tracked 113 health and biotech venture rounds in 2026 totaling $8.9B.
Still unconfirmed
- TechCrunch Disrupt 2026 Startup Battlefield 200 included industry-defining companies
What to watch next
- The full criteria for the Endpoints 11 selection
- Further funding rounds for Azalea Therapeutics and Medici
- Progress of Azalea Therapeutics' cancer immunotherapy and CAR-T technologies
confidence 100%Sources used for this update (4)
- www.nytimes.com — Latest Polls
- valueaddvc.com — Top Health & Biotech Startups 2026: Rounds, Valuations &…
- fundingwatcher.com — Top biotech startups: 10,172 (October 2026) | FundingWatcher
- techcrunch.com — TechCrunch Disrupt 2026 Startup Battlefield 200: Celebrating ...
-
Azalea Therapeutics and Medici named to 2026 Endpoints 11 list
Azalea Therapeutics and Medici, both startups founded by Parker Institute investigators, earned spots on the 2026 Endpoints 11 list of the most exciting biotechnology companies. Azalea focuses on cancer immunotherapy and CAR-T technologies. These recognitions highlight the transition of academic research into commercial ventures within the oncology sector. The list identifies high-potential startups based on their technical approach and leadership, though the full criteria for the Endpoints 11 selection remain unspecified in the available reports.
Why it matters
The Endpoints 11 serves as an annual benchmark for identifying emerging leaders in biotechnology. These companies often leverage specialized research from academic institutes to develop novel cancer treatments. Their inclusion on such lists can influence future venture capital interest and partnership opportunities.
What is confirmed
- Azalea Therapeutics and Medici are startups founded by Parker Institute investigators.
- Azalea Therapeutics and Medici were named to the 2026 Endpoints 11 list.
- Azalea Therapeutics focuses on cancer and CAR-T immunotherapy.
What to watch next
- Public disclosure of the remaining nine companies on the Endpoints 11 list
- Announcement of new funding rounds for Azalea Therapeutics or Medici
confidence 100%Sources used for this update (3)
- www.biospace.com — Startups - BioSpace
- oncodaily.com — Two Parker Institute-Founded Startups Named Among Biotech’s ...
- oncodaily.com — Parker Institute Investigators’ Startups Azalea and Medici ...
-
Biotech Markets Track Startups and Funding
Biotechnology market activity advances as analysts monitor public market entries, venture capital rounds, and regional development grants across the sector. BioSpace tracks United States biotechs entering public markets, recording 25 biopharma initial public offerings that generated approximately $7.6 billion in gross proceeds. Additional market data highlights 200 recently funded startups that secured venture backing over a recent sixty-day window, while the Wisconsin BioHealth Tech Hub received a $49 million grant from the U.S. Department of Commerce. Industry platforms and legislative bodies continue covering news, drug development, clinical trials, and national security intersections.
Why it matters
The biotechnology sector encompasses the use of living organisms and biological systems to build healthcare and industrial products. Tracking mechanisms like initial public offering dashboards provide transparency into capital formation for young biopharma companies. Specialized outlets and legislative advisory groups monitor these shifts to evaluate both commercial progress and policy implications.
What is confirmed
- BioSpace tracks United States biotechs entering public markets through a dedicated initial public offering dashboard.
- Twenty-five biopharma initial public offerings have priced in 2026, generating approximately $7.6 billion in gross proceeds.
- Two hundred recently funded startups secured venture backing over a recent sixty-day window.
- The Wisconsin BioHealth Tech Hub received a $49 million grant from the U.S. Department of Commerce.
What to watch next
- Future initial public offering pricing totals and venture funding updates for 2026 biopharma startups.
- Progress reports from the Wisconsin BioHealth Tech Hub regarding the deployment of its $49 million federal grant.
confidence 100%Sources used for this update (6)
- builtin.com — What Is Biotech? Biotech Definition and Types of Biotech. | Built...
- www.biotechtv.com — BiotechTV | Bringing the Biotech Sector to Life
- www.scientificamerican.com — Biotech - Scientific American
- www.biotech.senate.gov — Home - Biotech
- www.fiercebiotech.com — Biotech | Fierce Biotech
- biotechbridge.org — What is Biotech? - BioBridge
-
Biotech Market Activity Advances With VC Funding and Public Offerings
Biotechnology market activity advances as analysts track newly public companies, venture capital funding rounds, and major regional grants. BioSpace launched an initial public offering dashboard to monitor United States biotechs entering public markets during the year. Tracking data reveals that 25 biopharma initial public offerings have priced in 2026, generating approximately $7.6 billion in gross proceeds. Additional market data highlights 200 recently funded startups that secured venture backing over a recent sixty-day window. Meanwhile, the Wisconsin BioHealth Tech Hub received a $49 million grant from the U.S. Department of Commerce.
Why it matters
The biotechnology sector integrates natural sciences and engineering to produce valuable substances and services using living organisms. Regulatory compliance, manufacturing standards, and specialized research services remain critical to the development of healthcare products globally. Regional technology hubs also leverage local academic and corporate strengths to advance personalized medicine and data analysis.
What is confirmed
- BioSpace launched an initial public offering dashboard to monitor United States biotechs that entered public markets during 2026.
- 25 biopharma initial public offerings have priced in 2026, generating approximately $7.6 billion in gross proceeds.
- 200 recently funded startups secured venture backing over a recent sixty-day window.
- The Wisconsin BioHealth Tech Hub was named one of 12 tech hubs to receive Phase 2 funding from the U.S. Department of Commerce Regional Technology and Innovations Hub program.
- The Wisconsin BioHealth Tech Hub received a $49 million grant.
Still unconfirmed
- Twenty founders earned a spot to compete for a $100,000 prize and the Disrupt Cup at TechCrunch Disrupt.
What to watch next
- Further developments on the $49 million grant impact at the Wisconsin BioHealth Tech Hub
- Additional pricing of biopharma initial public offerings through the remainder of 2026
confidence 100%Sources used for this update (9)
- www.biotechxray.com — BioTech X-ray Inc. | Experience Portable Imaging Today
- www.biotechclinical.com — Biotech Clinical
- biotech.com — About Us - PSC Biotech®
- www.biotechpharmacal.com — Bio-Tech Pharmacal | Best Vitamin D & All-Natural Supplements
- en.wikipedia.org — Biotechnology - Wikipedia
- biotech.wisc.edu — BIOTECHNOLOGY CENTER – Innovative Biotechnology that Shapes ...
- www.employmilwaukee.org — BioHealth Tech Hub
- biotech.com — Home | PSC BIOTECH® Your Strategic Partner in Life Sciences
- techcrunch.com — The 2026 Startup Battlefield Top 20: From organs to orbit and everything in between
-
Biotech Funding and IPO Activity Continues Through October 2026
Biotech market activity moves forward in October 2026 as analysts track newly public companies and venture capital funding rounds. BioSpace launched an initial public offering dashboard to monitor United States biotechs that entered public markets during the year. Meanwhile, tracking data shows that 25 biopharma initial public offerings have priced in 2026, generating approximately $7.6 billion in gross proceeds. Additional market data highlights 200 recently funded startups that secured venture backing over a recent sixty-day window, reflecting ongoing capital flow across the sector.
Why it matters
Tracking public listings and venture investments provides critical visibility into the financial health of the biotechnology sector following the announcement of industry startup awards in late September. Financial monitors help industry observers evaluate post-listing performance and gross proceeds for newly public biopharma companies. These tracking mechanisms follow capital deployment across diverse therapeutic fields as firms advance through clinical and commercial pipelines.
What is confirmed
- BioSpace launched an IPO dashboard to monitor U.S. biotechs that went public in 2026.
- A biotech IPO tracker lists 25 priced offerings raising approximately $7.6 billion.
Still unconfirmed
- Venture-backed platforms list 200 startups that secured funding over the last 60 days.
What to watch next
- Further updates to the BioSpace IPO dashboard tracking newly public biotechs
- Ongoing adjustments to total gross proceeds and pricing data across 2026 biopharma IPO trackers
confidence 90%Sources used for this update (4)
- www.today.com — ‘Dancing With the Stars’ Cast 2026: Who’s Competing on Season 35
- www.biospace.com — 2026 IPO stock tracker: How newly public biotechs are ...
- www.vcbacked.co — Trending Startups (October 2026) - 200 Recently Funded | VCBacked
- www.biobucks.co — Biotech IPO Tracker 2026: 23 IPOs, ~$7.4B Raised
-
Endpoints News Names 2026 Most Promising Biotech Startups
Endpoints News announced the winners of the 2026 Endpoints 11 awards on September 25, 2026. The list identifies 11 biotech startups selected from over 150 nominations submitted by investors, industry leaders, and a Nobel Prize winner. This year's honorees include K2 Therapeutics and Corsera Health. The selected companies focus on diverse innovative fields, including mRNA therapies, AI-driven drug discovery, in vivo CAR-T, antibody-drug conjugates, RNA interference, T-cell engagers, and new human tissue models.
Why it matters
The Endpoints 11 awards serve as a benchmark for identifying high-potential early-stage companies in the biopharma sector. These recognitions often highlight the specific technological trends currently attracting venture capital and scientific interest.
What is confirmed
- Endpoints News announced the 2026 winners of the Endpoints 11 awards on September 25, 2026.
- The 2026 Endpoints 11 winners include Corsera Health and K2 Therapeutics.
- The selection process involved over 150 nominations from investors, industry leaders, and a Nobel Prize winner.
- The 11 selected companies target areas such as AI-driven drug discovery, T-cell engagers, antibody-drug conjugates, RNA interference, mRNA therapy, in vivo CAR-T, and new human tissue models.
confidence 100%Sources used for this update (6)
- www.fiercebiotech.com — Fierce Biotech Fundraising Tracker 2026
- news.europawire.eu — Roche reports phase III evERA results showing giredestrant plus everolimus extended progression-free survival in advanced ER-positive breast cancer
- article.wn.com — Endpoints News Announces the 2026 Winners of the Endpoints 11 ...
- article.wn.com — Endpoints News Announces the 2026 Winners of the Endpoints 11 ...
- fundraiseinsider.com — List of Funded Biotech Startups (2026) - Fundraise Insider
- news.qq.com — 2026“生物医药最具潜力新锐”榜单出炉！这11家公司瞄准哪些方向？
-
Endpoints News announces 2026 Endpoints 11 winners
Endpoints News unveiled the 2026 Endpoints 11 winners, honoring biotech's most exciting startups. The list was selected from over 150 nominations by industry leaders, investors, and a Nobel Prize winner. This year's winners include Corsera Health and K2 Therapeutics. The Endpoints 11 awards recognize compelling startups in biotech.
Why it matters
The Endpoints 11 awards highlight emerging biotech companies making significant contributions to the industry. These startups are working on innovative therapies and technologies. The awards have become a benchmark for excellence in biotech.
What is confirmed
- Endpoints News announced the 2026 Endpoints 11 winners on September 25, 2026.
- The list was selected from over 150 nominations by industry leaders, investors, and a Nobel Prize winner.
- Corsera Health was named a 2026 Endpoints 11 honoree.
- K2 Therapeutics was recognized as a 2026 Endpoints 11 honoree.
What to watch next
- Further details on the selected startups' technologies and therapies
- The impact of the Endpoints 11 awards on the biotech industry
- Future announcements from the awarded companies
confidence 85%Sources used for this update (9)
- Endpoints News — Biotech's most exciting startups of 2026: Meet this year's Endpoints 11
- Business Wire — Corsera Health Named a 2026 “Endpoints 11” Honoree
- The Manila Times — K2 Therapeutics Recognized as a 2026 Endpoints 11 Honoree
- TipRanks — Recognition and Global Development Model Highlight K2 THERAPEUTICS Strategy
- natlawreview.com — Endpoints News Announces the 2026 Winners of the Endpoints 11 Awards, showcasing biotech’s most exciting startups
- finance.yahoo.com — Endpoints News Announces the 2026 Winners of the Endpoints 11 ...
- events.endpoints.news — Endpoints 11 biopharma’s most promising startups in 2026
- www.financialcontent.com — Endpoints News Announces the 2026 Winners of the Endpoints 11 ...
- lifestyle.kotaradio.com — Endpoints News Announces the 2026 Winners of the Endpoints 11 ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community